Related Experiment Video
Updated: Aug 8, 2026
07:47
A Protocol For Uncovering Neural Mechanisms Of Neurotherapeutic Effects On Electroencephalography Using The Human Neocortical Neurosolver
Published on: May 19, 2026
Brexanolone, a First-In-Class Neurosteroid Medication: Mechanism of Action, Clinical, and Translational Science
Laura Gayanova1, Katrina Sian1, Jason Wells1
1Duquesne University Nasuti College of Osteopathic Medicine, Pittsburgh, Pennsylvania, USA.
Clinical and Translational Science
|August 7, 2026
Summary
Brexanolone, an IV treatment for postpartum depression (PPD), offers rapid symptom relief by modulating GABAA receptors. Despite its efficacy, its use is restricted by administration requirements and safety monitoring.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Postpartum depression (PPD) is a significant concern with increasing prevalence.
- Stigma surrounding PPD necessitates effective and accessible treatments.
- Brexanolone offers a novel therapeutic option for PPD.
Purpose of the Study:
- To review the efficacy and clinical use of brexanolone for PPD.
- To discuss brexanolone's mechanism of action and pharmacokinetic profile.
- To explore potential expanded indications for brexanolone.
Main Methods:
- Review of FDA-approved treatment brexanolone for PPD.
- Analysis of brexanolone's mechanism as a positive-allosteric modulator of GABAA receptors.
- Examination of brexanolone's pharmacokinetic properties, including metabolism and renal impairment considerations.
Main Results:
- Brexanolone demonstrates rapid onset and lasting reduction in PPD symptoms.
- Significant symptom reduction observed by end of 60-h infusion and maintained through Day 30.
- Brexanolone is metabolized via non-CYP pathways, requiring no dose adjustment for mild-to-severe renal impairment.
Conclusions:
- Brexanolone is an effective IV treatment for PPD with a rapid onset of action.
- Clinical use is limited by a required 60-h infusion and REMS program enrollment.
- Further research into alternative delivery methods and expanded indications may enhance brexanolone's utility.
Related Concept Videos
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...